Medipath adds AI diagnostics to pathology labs
AI diagnostics company Ibex Medical Analytics has partnered Medipath, the largest network of private pathology labs in France.
Israel-based Ibex will provide its AI-based decision support platform to assist diagnoses in Medipath’s pathology labs, as part of the partnership. The two companies will also co-develop Ibex’s future products.
Medipath chairman Olivier Vire said: “We strongly believe in the value proposition of artificial intelligence in healthcare and specifically in pathology, and are proud to partner with Ibex, which is at the heart of the development and implementation of AI for pathology labs and cancer diagnoses.”
Ibex’s AI cancer diagnosis solution involves deep learning algorithms developed by data scientists, software engineers and pathologists. Its Second Read System for prostate cancer is the first AI-driven diagnostics application in clinical use in a pathology lab.
Ibex – which raised $11 million towards expansion in March – also has partnerships with Maccabi Healthcare Services and the University of Pittsburgh Medical Center.
Medipath and Ibex will present initial outcomes from the partnership at the European Congress of Pathology next week in Nice, France.
Related Content
Gatsby: a benchmark for STEM success
The Gatsby Foundation’s benchmarks are helping transform school careers guidance. Good news for STEM employers, says Rachel Bibby, who explains …
When plasma leaves the laboratory
The orbital laboratory is evolving into something more ambitious, a controlled industrial environment for producing next-generation materials, explains Ed Smith and Andrew Griffiths. …
London Lab Live: A capital investment
Launched last year as part of the Future Labs’ stable, the London show looks here to stay. One year on, …
